Therapeutic Area Manager Oncology, Switzerland - Zug, Schweiz - Stemline Therapeutics

Beschreibung

Overview:

Therapeutic Area Manager Oncology, Switzerland - Romandie

Reports to Country Manager Austria & Switzerland
**The Opportunity
The TAM is responsible for the sale and support of Stemline products to both existing and potential customers.

The goals of this position are to acquire new customer business, increase market share through acquiring new accounts or expanding business in current customers, develop and encourage strong customer relationships, build brand loyalty, and to provide customer satisfaction.

It is a role with an extremely high level of autonomy, visibility, and the unique chance to influence how Stemline is positioned in Switzerland.

Responsibilities:

• Identification of key local medical professionals in relevant disease areas for Stemline and establish and maintain professional relationships with these stakeholders.
• Assessment of patient journeys, discovering gaps and setting up plans in collaboration with the crossfunctional team to ensure that Stemlines's medicines will effectively and safely reach the patients who need them.
• Taking initiative and working hand in hand with Medical Affairs and Market Access in implementing disease awareness campaigns, and interdisciplinary professional projects in Switzerland in accordance with the respective strategic plans.
• Provision of all relevant information related to approved Stemline products necessary to ensure their most effective and safe usage in the right patients according to clinical data, label and prescribing information.
• Development and implementation of appropriate measures within the agreed strategic objectives to drive inlabel usage of Stemline's approved products within the right patient group as per respective label and prescribing information.
• Providing support to medical professionals and treatment centres on any ordering and reimbursement aspects related to Stemline products.
• Operational and strategic contribution to market development project plans in close collaboration with the local crossfunctional team.
• General support of various field market access activities in close collaboration and under the guidance of Market Access.
• Ensuring full compliance in all customer engagement efforts according to Stemline's SOPs as well as local laws and regulations.

Qualifications:

• Experienced KAM, at least 5 years of field experience in the pharmaceutical industry in Switzerland
• Previous experience working in the area of Hematology/Oncology and preferred is experience in breast cancer
• Proven interest/expertise in scientific and clinical aspects paired with an entrepreneurial attitude and a tenacious ambition for commercial success
• Outspoken and positive attitude in benefit/price aspects of innovative pharmaceutical products
• Robust understanding of local reimbursement mechanisms, willing to engage with and support centres in reimbursement aspects
• Strong intellectual and communication skills
• Highly selfmotivated, handson and acting independently
• The role will be 100% fieldbased covering the assigned territory, requiring a high level of travel and mobility
• French (business fluent), German (fluency strongly preferred), English (good level)
• Menarini Stemline is an equalopportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees_

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group's headquarters are still located today.

High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability.

These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world.

Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours.

The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini's oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacy